Literature DB >> 18837951

Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients.

Olga E Bryzgunova1, Evgeniy S Morozkin, Sergey V Yarmoschuk, Valentin V Vlassov, Pavel P Laktionov.   

Abstract

Hypermethylated promoters of cancer-related genes represent convenient targets for early cancer diagnosis and monitoring based on circulating/extracellular DNA (cir/exDNA) from human blood and urine. The frequency of detection of methylated tumor suppressor genes in plasma or urine samples is usually lower than in the samples of tumor tissue because of a low concentration of target DNA and potential polymorphism of cirDNA methylation. Sequencing of the methylated cir/exDNA of tumor suppression genes provides information about methylation of the cirDNA originating from the tumor cells, which is necessary for optimization of cancer diagnosis. In this work, by sequencing chemically converted cir/exDNA, we have studied the cytosine methylation profile of GSTP1 gene promoter (1001-1302, X08058) in the pool of cir/exDNA from the blood and urine of healthy men, prostate cancer (PCa) patients, and patients with benign prostatic hyperplasia (BPH). We demonstrated that the data on cir/exDNA methylation could be obtained from sequencing of the cir/exDNA from blood and urine. The DNA isolated from blood plasma and the eluates of blood cells and urine of each patient were characterized by the same methylation profile of the GSTP1 gene. The profile of GSTP1 gene methylation in the extracellular DNA of PCa patients differs from the profiles characteristic of healthy donors and patients with BPH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837951     DOI: 10.1196/annals.1448.039

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  30 in total

1.  HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.

Authors:  Xiaohua Li; Alexander Kaplun; Fulvio Lonardo; Elisabeth Heath; Fazlul H Sarkar; Jonathan Irish; Wael Sakr; Shijie Sheng
Journal:  Mol Cancer Res       Date:  2011-05-26       Impact factor: 5.852

Review 2.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

Review 3.  Prostate cancer: the need for biomarkers and new therapeutic targets.

Authors:  Juliana Felgueiras; Joana Vieira Silva; Margarida Fardilha
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

Review 4.  Cancer control and prevention by nutrition and epigenetic approaches.

Authors:  Mukesh Verma
Journal:  Antioxid Redox Signal       Date:  2012-01-30       Impact factor: 8.401

Review 5.  Screening for pancreatic cancer: why, how, and who?

Authors:  Katherine E Poruk; Matthew A Firpo; Douglas G Adler; Sean J Mulvihill
Journal:  Ann Surg       Date:  2013-01       Impact factor: 12.969

6.  6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage.

Authors:  Kostyantyn A Nekrasov; Mark V Vikarchuk; Evgeniya E Rudenko; Igor V Ivanitskiy; Viacheslav M Grygorenko; Rostyslav O Danylets; Alexander G Kondratov; Liubov A Stoliar; Bizhan R Sharopov; Volodymyr I Kashuba
Journal:  Oncol Lett       Date:  2019-10-29       Impact factor: 2.967

Review 7.  Urinary Biomarkers in Tumors: An Overview.

Authors:  Ilaria Cimmino; Sara Bravaccini; Claudio Cerchione
Journal:  Methods Mol Biol       Date:  2021

Review 8.  Clinical applications of urinary cell-free DNA in cancer: current insights and promising future.

Authors:  Tian Lu; Jinming Li
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

Review 9.  DNA methylation changes in prostate cancer: current developments and future clinical implementation.

Authors:  Mohammad Obaidul Hoque
Journal:  Expert Rev Mol Diagn       Date:  2009-04       Impact factor: 5.225

10.  Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays.

Authors:  Ken Kron; Vaijayanti Pethe; Laurent Briollais; Bekim Sadikovic; Hilmi Ozcelik; Alia Sunderji; Vasundara Venkateswaran; Jehonathan Pinthus; Neil Fleshner; Theodorus van der Kwast; Bharati Bapat
Journal:  PLoS One       Date:  2009-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.